CO6341621A2 - Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1 - Google Patents

Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1

Info

Publication number
CO6341621A2
CO6341621A2 CO11072655A CO11072655A CO6341621A2 CO 6341621 A2 CO6341621 A2 CO 6341621A2 CO 11072655 A CO11072655 A CO 11072655A CO 11072655 A CO11072655 A CO 11072655A CO 6341621 A2 CO6341621 A2 CO 6341621A2
Authority
CO
Colombia
Prior art keywords
halogen
heteroaryl
lower alkyl
alkyl
lower alkoxy
Prior art date
Application number
CO11072655A
Other languages
English (en)
Inventor
Sabine Kolczewski
Emmanuel Pinard
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6341621A2 publication Critical patent/CO6341621A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La presente invención se refiere a un compuesto de la fórmula general Ien la queR1 es hidrógeno, alquilo inferior, CD3, -(CH2)n-CHO, -(CH2)n,-O-alquilo inferior, -(CH2)n-OH, -(CH2)n-cicloalquilo o es heterocicloalquilo;R2 es hidrógeno, halógeno, hidroxi, alquilo inferior, dialquilo inferior, -OCH2-O-alquilo interior o alcoxi inferior; o el anillo piperidina junto con R2 forma un anillo espiro, elegido entre 4-aza-espiro [2.5] oct-6-ilo;Ar es arilo o heteroarilo, que están opcionalmente sustituidos por uno, dos o tres sustituyentes elegidos entre halógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior sustituido por halógeno! cicloalquilo, alcoxi inferior, 5-alquilo inferior, heteroarilo, heterocicloalquilo o por fenilo opcionalmente sustituido por R' yR1 es halógeno, alquilo inferior, alcoxi inferior o alcoxi inferior sustituido por halógeno, o es heteroarilo;R es alquilo inferior, cicloalquilo, heterocicloalquilo, arilo o heteroarilo, dichos arilo y heteroarilo están opcionalmente sustituidos por uno o dos R':n es el número 0,1, 2 ó 3;o a una sal de edición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico correspondiente.La presente invención se refiere además a composiciones farmacéuticas que contienen los compuestos de la fórmula I y a su utilización para el tratamiento de trastornos neurológicos y neuropsiquiátricos.
CO11072655A 2009-01-27 2011-06-10 Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1 CO6341621A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09151382 2009-01-27

Publications (1)

Publication Number Publication Date
CO6341621A2 true CO6341621A2 (es) 2011-11-21

Family

ID=41718529

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11072655A CO6341621A2 (es) 2009-01-27 2011-06-10 Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1

Country Status (24)

Country Link
US (2) US20100197715A1 (es)
EP (1) EP2391603B1 (es)
JP (1) JP5552494B2 (es)
KR (1) KR101289577B1 (es)
CN (1) CN102292320B (es)
AR (1) AR075160A1 (es)
AU (1) AU2010209816A1 (es)
BR (1) BRPI1007410A2 (es)
CA (1) CA2746967A1 (es)
CO (1) CO6341621A2 (es)
CR (1) CR20110348A (es)
EC (1) ECSP11011196A (es)
ES (1) ES2445143T3 (es)
IL (1) IL213672A0 (es)
MA (1) MA32947B1 (es)
MX (1) MX2011007272A (es)
NZ (1) NZ593279A (es)
PE (1) PE20120500A1 (es)
RU (1) RU2517701C2 (es)
SG (1) SG173116A1 (es)
TW (1) TWI403322B (es)
UA (1) UA104611C2 (es)
WO (1) WO2010086251A1 (es)
ZA (1) ZA201104237B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2746967A1 (en) 2009-01-27 2010-08-05 F. Hoffmann-La Roche Ag Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
US8658639B2 (en) * 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
US20140155419A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
US9012489B2 (en) 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2021092407A1 (en) * 2019-11-07 2021-05-14 The Board Of Trustees Of The University Of Illinois Inhibitors of influenza viral entry
CN114478360B (zh) * 2022-02-10 2023-08-15 江苏海洋大学 一种苯甲酰胺类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2600557A1 (de) * 1976-01-09 1977-07-14 Delmar Chem 4-aryl-3/4-amino/hydroxy-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU2001254546A1 (en) * 2000-04-20 2001-11-07 Nps Allelix Corp. Aminopiperidines
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
EP1594840B1 (en) * 2003-02-17 2006-09-27 F. Hoffmann-La Roche Ag Piperidine-benzenesulfonamide derivatives
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
WO2005040166A1 (en) 2003-10-23 2005-05-06 F.Hoffmann-La Roche Ag Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders
WO2008093737A1 (ja) * 2007-01-31 2008-08-07 Dainippon Sumitomo Pharma Co., Ltd. アミド誘導体
UA41251U (ru) * 2008-12-26 2009-05-12 Яков Семенович Песиков Способ лечения алкоголизма
CA2746967A1 (en) 2009-01-27 2010-08-05 F. Hoffmann-La Roche Ag Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors

Also Published As

Publication number Publication date
KR101289577B1 (ko) 2013-07-24
RU2517701C2 (ru) 2014-05-27
PE20120500A1 (es) 2012-05-04
ES2445143T3 (es) 2014-02-28
US20100197715A1 (en) 2010-08-05
MA32947B1 (fr) 2012-01-02
SG173116A1 (en) 2011-08-29
CN102292320B (zh) 2014-07-02
CR20110348A (es) 2011-09-06
AR075160A1 (es) 2011-03-16
CN102292320A (zh) 2011-12-21
US9067911B2 (en) 2015-06-30
EP2391603A1 (en) 2011-12-07
TWI403322B (zh) 2013-08-01
UA104611C2 (en) 2014-02-25
IL213672A0 (en) 2011-07-31
US20130158050A1 (en) 2013-06-20
EP2391603B1 (en) 2014-01-08
AU2010209816A1 (en) 2011-08-11
ZA201104237B (en) 2012-02-29
MX2011007272A (es) 2011-08-08
RU2011134960A (ru) 2013-03-10
KR20110107863A (ko) 2011-10-04
CA2746967A1 (en) 2010-08-05
TW201032803A (en) 2010-09-16
NZ593279A (en) 2013-03-28
JP2012515744A (ja) 2012-07-12
WO2010086251A1 (en) 2010-08-05
ECSP11011196A (es) 2011-08-31
BRPI1007410A2 (pt) 2016-02-16
JP5552494B2 (ja) 2014-07-16

Similar Documents

Publication Publication Date Title
CO6341621A2 (es) Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR078756A1 (es) Moduladores alostericos positivos (map)
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
AR074966A1 (es) Compuestos amino-heterociclicos
CO6761320A2 (es) Derivados de piperidina puenteada
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
EA201201052A1 (ru) Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk
AR084412A1 (es) Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
AR084515A1 (es) Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
AR086024A1 (es) Derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina carboxamidas

Legal Events

Date Code Title Description
FG Application granted